The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of thymosin alpha-1 (TA1) are reviewed. Clinical trials of TA1 for chronic hepatitis B or C ...

TA1 is supplied in single-use vials containing 1.6 mg of lyophilized product. After reconstitution with 1 mL of sterile water, TA1 is to be administered via subcutaneous injection. It should not ...